All articles tagged with #myasthenia gravis
Tennis legend Monica Seles has revealed her diagnosis with myasthenia gravis, a chronic autoimmune neuromuscular disease, sharing her journey of adapting to the condition and raising awareness ahead of the U.S. Open.
Tennis legend Monica Seles has publicly shared her diagnosis of myasthenia gravis, a rare autoimmune neuromuscular disorder, to raise awareness and help others dealing with similar health challenges. She described her symptoms, the impact on her life, and her motivation to advocate for understanding and support for the disease.
Tennis legend Monica Seles has revealed her diagnosis of myasthenia gravis, a rare autoimmune neuromuscular disease, to raise awareness. The disease causes muscle weakness and fatigue, affecting her daily life, and has no cure but can be managed with treatment. Seles shared her experience ahead of the U.S. Open to educate others about the condition.
Tennis legend Monica Seles revealed she has been living with myasthenia gravis since 2022, a neuromuscular autoimmune disease causing muscle weakness and double vision, which has significantly impacted her daily life. She discussed her ongoing adjustments and resilience, drawing parallels to her past life resets after moving to the U.S. and recovering from a stabbing incident, emphasizing the importance of adaptation.
Former tennis star Monica Seles revealed she was diagnosed with myasthenia gravis, a chronic neuromuscular autoimmune disease, three years ago. She shared her journey with the condition to raise awareness and discussed how she has adapted to her 'new normal' through multiple life resets, including her early life, tennis career, and health challenges.
Dr. Keith Roach addresses concerns about a potential link between statin use and the development of myasthenia gravis (MG) in seniors. While some case reports suggest a possible association, the evidence is not strong enough to consider MG a significant risk factor when starting statins. However, individuals with existing MG should monitor for symptom worsening. Alternatives to statins, such as bile acid sequestrants and PCSK-9 inhibitors, may pose less risk to muscle health.
The FDA has approved UCB's Rystiggo, a treatment for generalized myasthenia gravis, making it the first drug to receive approval for both main subtypes of the rare autoimmune disease. UCB plans to make the under-the-skin treatment commercially available in the third quarter, following the recent approval of argenx's Vyvgart Hytrulo in subcutaneous form.
Cartesian Therapeutics' experimental CAR-T cell therapy shows promise in treating Myasthenia Gravis, a disease where the immune system attacks and destroys the junctions between nerves and muscles. A North Carolina forester suffering from the disease found hope in the treatment after struggling with leg and arm weakness.
A modified form of CAR-T therapy, known as Descartes-08, has shown promise in treating myasthenia gravis, an autoimmune disorder of the nervous system. The therapy targets the cells responsible for producing myasthenia gravis-causing antibodies and offers the potential for a longer-lasting reduction in symptoms. The therapy was well-tolerated without significant adverse effects in a small-scale clinical trial. The ideal dosage was determined to be once weekly for six weeks. The therapy is now being tested in a larger clinical trial to determine its ability to reduce myasthenia gravis symptoms.
The FDA has approved a new injectable version of argenx's autoimmune disease drug Vyvgart, marketed as Vyvgart Hytrulo, for people with generalized myasthenia gravis. The condition causes a person's immune system to make antibodies that attack their muscles, making movement, speaking, and swallowing difficult and life-threatening when it impedes breathing. The new version will be available in July.